Easywell Biomedicals (ROCO:1799) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1799 Easywell Biomedicals Inc ROCO:1799
55 GF Score
Price NT$32.25
GF Value NT$75.37
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Easywell Biomedicals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Easywell Biomedicals Valuation Rank Related Terms

ROCO:1799
55GF Score
Easywell Biomedicals Inc ROCO:1799
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?

Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued. The current stock price of NT$32.25 is trading 57.2% below its estimated GF Value™ of NT$75.37. GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.

Key valuation signals for ROCO:1799:

  • Valuation Rank:
  • GF Value™: NT$75.37 vs. price of NT$32.25 (57.2% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Easywell Biomedicals Business Description

Address No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
55GF Score

Get the complete analysis for ROCO:1799

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.25
Price
NT$75.37
GF Value